# Tao Jiang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tao-jiang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,979 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 49 |
| i10-index | 124 |
| Last Known Institution | Shanghai Pulmonary Hospital |
| OpenAlex ID | https://openalex.org/A5100763327 |
| ORCID iD | 0000-0002-9205-8183 |
| Works | 348 |

## Researcher papers

- [Role of IL-2 in cancer immunotherapy](https://scholariq.org/papers/role-of-il-2-in-cancer-immunotherapy/)
- [Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients](https://scholariq.org/papers/investigating-novel-resistance-mechanisms-to-third-generation-egfr-tyrosine/)
- [TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway](https://scholariq.org/papers/timp1-is-a-prognostic-marker-for-the-progression-and-metastasis-of-colon-cancer/)
- [Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer](https://scholariq.org/papers/low-dose-apatinib-optimizes-tumor-microenvironment-and-potentiates-antitumor/)
- [Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-paclitaxel-as-first-line-treatment-for/)
- [Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer](https://scholariq.org/papers/combined-radiotherapy-and-anti-pd-l1-antibody-synergistically-enhances-antitumor/)
- [HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib](https://scholariq.org/papers/her2-exon-20-insertions-in-non-small-cell-lung-cancer-are-sensitive-to-the/)
- [Early detection of lung cancer by using an autoantibody panel in Chinese population](https://scholariq.org/papers/early-detection-of-lung-cancer-by-using-an-autoantibody-panel-in-chinese/)
- [Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs](https://scholariq.org/papers/consolidative-local-ablative-therapy-improves-the-survival-of-patients-with/)
- [Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?](https://scholariq.org/papers/immune-checkpoint-inhibitors-in-egfr-mutated-nsclc-dusk-or-dawn/)
- [P1.01-22 Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC](https://scholariq.org/papers/p1-01-22-investigation-of-acquired-resistance-for-egfr-tki-plus-bevacizumab-as/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Shanghai Pulmonary Hospital](https://scholariq.org/institutions/shanghai-pulmonary-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.